Incyte - INCY Stock Forecast, Price & News

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Incyte Stock Up 0.3 %

Shares of NASDAQ:INCY opened at $72.16 on Monday. The company has a 50 day simple moving average of $76.16 and a 200-day simple moving average of $75.21. The company has a market capitalization of $16.05 billion, a P/E ratio of 16.98, a P/E/G ratio of 1.24 and a beta of 0.64. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.91 and a quick ratio of 3.67. Incyte has a 1 year low of $61.91 and a 1 year high of $84.86.

Incyte (NASDAQ:INCY - Get Rating) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.22. Incyte had a net margin of 28.46% and a return on equity of 13.02%. The firm had revenue of $911.40 million during the quarter, compared to the consensus estimate of $818.25 million. During the same quarter last year, the firm earned $0.65 EPS. The firm's revenue for the quarter was up 29.1% on a year-over-year basis. On average, equities research analysts predict that Incyte will post 2.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. StockNews.com raised Incyte from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, August 3rd. Oppenheimer lowered their target price on Incyte from $109.00 to $98.00 in a research report on Wednesday, August 3rd. Guggenheim downgraded Incyte from a "buy" rating to a "neutral" rating in a research report on Wednesday, August 3rd. Evercore ISI downgraded Incyte from an "outperform" rating to an "inline" rating and lowered their price objective for the company from $90.00 to $78.00 in a research report on Wednesday, August 3rd. Finally, TheStreet upgraded Incyte from a "c" rating to a "b" rating in a research report on Tuesday, August 2nd. One analyst has rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $84.92.

Insider Transactions at Incyte

In related news, EVP Vijay K. Iyengar sold 5,787 shares of the business's stock in a transaction on Thursday, July 7th. The shares were sold at an average price of $79.38, for a total value of $459,372.06. Following the completion of the sale, the executive vice president now directly owns 40,313 shares of the company's stock, valued at $3,200,045.94. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Incyte news, EVP Vijay K. Iyengar sold 5,787 shares of Incyte stock in a transaction on Thursday, July 7th. The shares were sold at an average price of $79.38, for a total value of $459,372.06. Following the transaction, the executive vice president now directly owns 40,313 shares in the company, valued at $3,200,045.94. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Thomas Tray sold 1,564 shares of the business's stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $83.13, for a total transaction of $130,015.32. Following the transaction, the insider now owns 17,702 shares in the company, valued at $1,471,567.26. The disclosure for this sale can be found here. Corporate insiders own 15.80% of the company's stock.